Sex: F
Vaccine: COVID19
Symptoms: Cellulitis, Influenza like illness, Sinus operation
Clinical narrative: Cellulitis; Sinus drainage due to the weather; Flu-like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of CELLULITIS (Cellulitis) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    Concurrent medical conditions included Plaque psoriasis.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced CELLULITIS (Cellulitis) (seriousness criterion medically significant), SINUS OPERATION (Sinus drainage due to the weather) and INFLUENZA LIKE ILLNESS (Flu-like symptoms). At the time of the report, CELLULITIS (Cellulitis) had resolved and SINUS OPERATION (Sinus drainage due to the weather) and INFLUENZA LIKE ILLNESS (Flu-like symptoms) outcome was unknown.            Concomitant medications were not reported.  Patient reported non-serious events of Flu-like symptoms, sinus drainage due to the weather and cellulitis with SKYRIZI(RISANKIZUMAB).  On unknown dates, the patient experienced Flu-like symptoms, sinus drainage due to the weather and cellulitis. On an unknown date, CELLULITIS was resolved. MODERNA COVID-19 VACCINE (COVID-19 VACCINE MRNA (MRNA 1273)) was also considered suspect.  Patient reported that she got cellulitis from her second dose of covid vaccine.  She was down with flulike symptoms for a couple days after her covid vaccines and also lots of sinus drainage due to the weather.  Treatment information was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company Comment: This is a spontaneous case concerning an elderly female patient with no relevant medical history, who experienced the unexpected, serious (medically significant) event of Cellulitis, after receiving the second dose of mRNA-1273 vaccine. Exact date of vaccination, onset date of the event, clinical course, diagnostic tests and treatment details were not provided in the case. The event had resolved at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning an elderly female patient with no relevant medical history, who experienced the unexpected, serious (medically significant) event of Cellulitis, after receiving the second dose of mRNA-1273 vaccine. Exact date of vaccination, onset date of the event, clinical course, diagnostic tests and treatment details were not provided in the case. The event had resolved at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.